EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene Editing for Haemophilia—The Next Frontier

Mirko Pinotti, Gregory A Newby, Sundar Selvaraj, Steven W Pipe

Haemophilia · 16.04.2026

DOI: 10.1111/hae.70238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 16.04.2026. Verfasst von Mirko Pinotti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Emilia-Romagna, Italy. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, Cystic Fibrosis Foundation, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults. Conversely, genome editing by precise gene correction or targeted transgene insertion could be translated to children and even neonates. Pioneer studies with Zinc‐Finger nucleases (ZFN) driving homologous directed repair (HDR) established the proof of concept for in vivo targeted integration. The advent of the much more versatile CRISPR‐Cas9 technology boosted research in the haemophilia field, and preclinical data demonstrated that targeted gene insertion of the F8/F9 coding sequence, can represent a durable therapy both in adults and neonates. Although with modest efficiency, the effect can be boosted by exploitation of the hyperactive FIX Padua and/or integration at a “smart” target locus of a highly expressed liver‐specific gene such as Albumin (Phase 1/2 trial). Moreover, targeted insertion has been achieved at the CCR5 locus to insert the FIX Padua via HDR in B lymphocytes, and this promising ex‐vivo gene therapy entered a Phase 1/2 trial. Base and prime editors have also been successfully exploited in cellular models to precisely correct gene defects but their translational potential is limited by the many diverse haemophilia‐causing genetic variants that need to be addressed. As these technologies mature, rigorous long‐term follow‐up and safety monitoring will be essential to offer patients a definitive cure for haemophilia.

Schlagwörter

Stichwörter der Autor:innen

CRISPRbase editingclinical trialsgene editinghaemophiliasafety

Autor:innen und Institutionen

  • Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Emilia-Romagna, Italy.
  • Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Institute of NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
  • Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Förderung

  • NIH
  • Cystic Fibrosis Foundation
  • British Heart Foundation
  • Solve GNE Foundation
  • Bill and Melinda Gates Foundation
  • National Institutes of Health

Zitieren

APA

Pinotti, M., Newby, G. A., Selvaraj, S., & Pipe, S. W. (2026). Gene Editing for Haemophilia—The Next Frontier. Haemophilia. https://doi.org/10.1111/hae.70238

Vancouver

Pinotti M, Newby GA, Selvaraj S, Pipe SW. Gene Editing for Haemophilia—The Next Frontier. Haemophilia. 2026. doi:10.1111/hae.70238

BibTeX
@article{Pinotti2026,
  author = {Pinotti, Mirko and Newby, Gregory A and Selvaraj, Sundar and Pipe, Steven W},
  title = {Gene Editing for Haemophilia—The Next Frontier},
  journal = {Haemophilia},
  year = {2026},
  doi = {10.1111/hae.70238}
}
Kostenlos starten →